Abstract:
Introduction

54
Porcine circovirus type 2 (PCV2) is the essential causative agent of a series of 55 diseases known as porcine circovirus diseases (PCVD) [1, 2] . Postweaning multisystemic 56 wasting syndrome (PMWS), currently denominated as PCV2-systemic disease (PCV2-SD), 57 is one of the most economically important PCVD, since it increases the mortality rate and 58 reduces production parameters [1, 3] . The effects derived from PCV2-SD have been 59 drastically reduced by the use of different available commercial vaccines at the worldwide 60 swine production market [4] .
61
Besides the contrasted efficacy of PCV2 vaccines, some field and experimental 62 studies have indicated that vaccination in face of high maternally derived antibody (MDA) 63 levels may affect such efficacy. This potential interference has been studied at two different 64 levels: vaccine-elicited humoral immune response and average daily weight gain (ADWG).
65
In terms of humoral response, it has been proven that high antibody levels at the moment of Both groups of animals had similar (p>0.05) ADWG and in consequence it was concluded 72 that this parameter was not affected by MDA level. However, the average titre for both 73 groups of animals was not provided in the paper, and apparently they were not sharply 74 different. Similarly, Fraile et al. [5] did not find statistically significant differences in terms 75 of ADWG between 4-week-old vaccinated piglets derived from vaccinated and non-76 vaccinated sows. However, the correlation between initial MDA and ADWG (in the double 77 vaccinated ones) showed a negative slope, suggesting a potential negative effect when 78 higher MDA titres were present at vaccination time. In Haake et al. [9] , pigs were 79 vaccinated at 1 or 3 weeks of age, which rendered different maturity of the immune system 80 as well as levels of MDA at the moment of vaccination. In that study, animals vaccinated at 81 3 weeks of age had a higher ADWG than the ones vaccinated at 1 week of age. When 82 compared, antibody titres of the pigs at 1 week of age were higher than those at 3 weeks of 83 age.
84
Based on these inconsistencies, the present study aimed to assess PCV2 vaccination 85 in terms of ADWG in purposely selected age-matched animals with high and low PCV2
86
ELISA S/P levels at the time of PCV2 vaccination. In addition, antibody and infection 87 dynamics as well as viral loads of these animals were studied. 
Materials and methods
90
Farm selection
91
The present study was conducted in a conventional Spanish multi-site production 92 system in which PCV2 vaccination of 3 week-old piglets (Porcilis PCV, MSD) was applied 93 routinely since 2 years before starting this study. An all-in-all-out management strategy was 94 used in both nursery and fattening units.
95
In order to assess PCV2 infection before the start of the study, blood samples from 96 10 animals of different ages (5, 9, 14, 18 and 24 weeks of age) were taken. These blood 97 samples were processed by standard PCR [11] . PCV2 genome was detected in 30% (3 out 98 of 10) and 40% (4 out of 10) of pigs at 14 and 18 weeks of age, respectively. All tested 99 samples from 5, 9 and 24 weeks of age were negative by PCR. 
Study design
102
To ensure the presence of different levels (from very low to very high) of PCV2
103
MDA titres at the moment of vaccination, a proportion of sows were vaccinated before 104 farrowing. Thus, from 64 randomly selected sows, 33 (52%) were vaccinated 105 intramuscularly (IM) (neck muscle, needle length: 1.2x40 mm) with 1 dose of 2 mL of 106 Circovac (Merial; batch number L383022) at 3 and 6 weeks pre-farrowing (V sows). The 107 remaining 31 sows were left non-vaccinated (NV sows).
108
At 2 weeks of age, all healthy piglets (n=572) born from these 64 sows were ear- 
PCR and quantitative PCR (QPCR)
137
DNA extracted from serum samples was processed by standard PCV2 PCR and 
166
Specific causes for such mortality were not investigated. In addition, 10 animals were 167 excluded from the study because of losing their ear tags. 
Comparisons between vaccinated and non-vaccinated pigs
PCR and QPCR
171
PCV2 was firstly detected in both treatments at 18 weeks of age (Fig.1) 
Body weight and ADWG
185
No statistical differences were found in the body weight between V and NV piglets 186 from the beginning to the end of the study (Table 2) . ADWG was significantly higher 187 (P<0.05) in V compared to NV during the 12-25 and 2-25 week-periods; specifically, V 188 animals gained 33 and 17g per day more than NV pigs, in the respective periods. L-V compared to NV groups at 18, 22 and 25 weeks of age and in H-V group compared to 195 NV groups at 22 and 25 weeks of age (Fig 3) . Between the two V groups, statistical significant differences were only found at 22 weeks of age (higher number of PCV2 PCR A sharp decrease (up to 12 weeks of age) of ELISA S/P values was observed in both
218
H groups (Fig 4B) . On the contrary, in the L groups the decrease in S/P values was seen 219 until 7 weeks of age. At that point, whereas L-V pigs showed a progressive increase of 220 ELISA S/P values, a flat line from 7 to 18 weeks of age was observed in L-NV ones.
221
Afterwards, all groups experienced an increase of ELISA S/P ratios being significantly 222 higher (P<0.05) in both NV groups than their V counterparts. At the two latter sampling 223 points, L-V pigs had significantly lower (P<0.05) ELISA S/P ratios than H-V ones. 
Discussion
235
The effect of MDA levels at vaccination age was assessed on ADWG as primary 236 outcome. The initial hypothesis was that the higher the MDA at vaccination timing, the 237 lower the ADWG. However, such hypothesis was not confirmed since a potential 238 detrimental effect of MDA on ADWG was not evident. Although L-V animals grew 2 and 239 18 g per day more than H-V ones in the 2-25 and 12-25 week periods, such differences 240 were not statistically significant. Besides, virological and serological parameters were also 241 studied. In the present study, pigs vaccinated with low MDA seemed to take more benefit of 242 the treatment than their counterparts with high MDA, since they had a lower PCV2 243 infection rate (at 22 weeks of age), lower AUC of viral load and showed an earlier seroconversion (evident at 12 weeks of age). These latter results would be in accordance 
Conclusion
295
Under the conditions of this study, vaccination at 3 weeks of age was able to 
